Tuesday, April 16, 2019

In the NEWS: Credence, Rise of the Nephron Throne

A positive light at the end of the tunnel for nephrology, the Credence trial just got published this week in NEJM, put the glucoretics on top for diabetic nephropathy. When you search “credence” in the oxford dictionary it means” belief in or acceptance of something as true”.  I think the time has come to believe that SGLT-2 inhibitors are here to stay and are going to change the disease of diabetic nephropathy.

In summary, this large RCT was stopped early. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group. The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34%  and the relative risk of end-stage kidney disease was lower by 32%. The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke and hospitalization for heart failure. There were no significant differences in rates of amputation or fracture.

Some of the twitter world made some amazing comments on this

Susan Quaggin‏ @SusanQuaggin19 years since RENAAL and IDNT..followed by a series of negative trials...but the drought is over! New therapies for our patients with diabetic kidney disease are a reality - #CREDENCE marks the beginning of a new era in Kidney Medicine "#SockItToKidneyDisease"

Juan Manuel Mejía‏ @Meyaix "Every nephrologist is now talking of #CREDENCE ."

Jennie Lin, MD MTR‏ @jenniejlin"#CREDENCE, landmark clinical trial for patients with T2DM and kidney disease, is now published: 30% lower relative risk for primary renal outcome in canagliflozin arm, with pretty darn significant p-value of 0.00001! It was thrilling to watch the results stream live from #ISNWCN!"

And my personal favorite....

Steven Coca‏ @scoca1 "You had me at “hello” before the gasp & applause for the tiny p value The separation of the KM curves (effect size) and 95% CI are what had me leaping And more fist pumping when the difference in eGFR slopes were shown"

While this drug was developed and marketed to treat diabetes, it is more than that. Someone on social media world rightly said” We have an anti HTN and renal protective med that has a nice side effect of lowering your A1c”

It decreases blood pressure
It induces weight loss
It decreases intraglomerular pressure
It is a proximal tubular diuretic
It is anti-inflammation
It decreases proteinuria

This is a nephrologist's drug! Finally, we have a positive trial in the making that is going to change the practice of nephrology. Diabetics, non-diabetics, HTN, CHF patients- all might benefit from this discovery!

No comments:

Post a Comment

All Posts

Search This Blog